Sclerostin and Adipose Tissue

Purpose of Review Since its discovery 15 years ago, inhibition of sclerostin has come to be identified as a potent anabolic agent. The sclerostin neutralizing antibody, romosozumab, is a promising treatment for postmenopausal osteoporosis. Animal studies also show a role of sclerostin in regulating hematopoietic cells and, more recently, adipocytes. This review will summarize the newly discovered effects of sclerostin on white, beige, and bone marrow adipocytes.